Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients

Shumin Yuan(Zhengzhou University), Zibing Wang(Huazhong University of Science and Technology), Xiang Yan(First Affiliated Hospital of Guangzhou University of Chinese Medicine), Hongle Li(Shanghai Jiao Tong University), Shaokai Zhang(Zhengzhou University), Jie Zhang(Xi'an Jiaotong University), Yuqing Liu(Central South University), Liping Zhu(Shihezi University), Quanli Gao(Zhengzhou University), Ling Peng(Zhejiang Shuren University), Huijuan Wang(Zhengzhou University), Brian G. Till(University of Washington)
Cancer Immunology Immunotherapy
August 5, 2022
10.1007/s00262-022-03259-5
Cited by 19

Related Papers

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
|Blood|2008|719
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
|Blood|2012|530
Scutellarin ameliorates pulmonary fibrosis through inhibiting NF-κB/NLRP3-mediated epithelial–mesenchymal transition and inflammation
|Cell Death and Disease|2020|387
MEK inhibitors for the treatment of non-small cell lung cancer
|Journal of Hematology & Oncology|2021|300
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies
|Blood|2020|217